Neurocrine Biosciences reaffirmed its financial outlook for INGREZZA, projecting $2.7 billion to $2.8 billion. The company also confirmed that its acquisition of Soleno Therapeutics is on track to close in the second quarter.

Neurocrine Biosciences has announced its intention to acquire Soleno Therapeutics in a transaction valued at approximately $2.9 billion.

Neurocrine Biosciences announced its plan to acquire Soleno Therapeutics, a move that will secure a drug designed to treat a relentless hunger disorder, specifically Prader-Willi syndrome. The acquisition aims to expand Neurocrine's therapeutic portfolio.

Neurocrine Biosciences has announced its acquisition of Soleno Therapeutics, thereby securing a promising drug designed to treat a rare genetic disorder characterized by relentless hunger.

Neurocrine Biosciences announced plans to acquire Soleno Therapeutics, aiming to secure a drug designed to treat a relentless hunger disorder.

Neurocrine Biosciences announced its intent to acquire Soleno Therapeutics, thereby obtaining a drug designed to treat a relentless hunger disorder.

Soleno Therapeutics (SLNO) continues to appear attractive to investors, even with slower U.S. launch ramp projections for its products.

Investors of BlackRock TCP Capital Corp. (NASDAQ: TCPC) are reminded by Kaplan Fox to contact them before the April 6, 2026 deadline regarding a class action lawsuit and potential recovery.

Kaplan Fox has issued an alert to investors regarding a securities class action lawsuit filed against Soleno Therapeutics, Inc., with a deadline of May 5, 2026.

Soleno Therapeutics, Inc. has released its summary for the Q4 2025 earnings call.

Multiple biotech and pharmaceutical companies, including Legend Biotech, Corcept Therapeutics, and Ultragenyx, have released updates on their drug pipelines, clinical trial data, and regulatory interactions, impacting market outlook.

Kessler Topaz Meltzer & Check, LLP has announced the filing of a securities fraud class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO).

Soleno Therapeutics (SLNO) shares soared by 32% following the announcement of a $2.9-billion merger.

Neurocrine Biosciences announced its intent to acquire Soleno Therapeutics, a move that will secure a drug designed to treat a relentless hunger disorder, expanding Neurocrine's therapeutic portfolio.

Neurocrine Biosciences announced its agreement to acquire Soleno Therapeutics, gaining access to its late-stage drug for Prader-Willi syndrome, a rare genetic disorder causing relentless hunger.

Neurocrine Biosciences has announced its intention to acquire Soleno Therapeutics, a move that will secure a drug for Prader-Willi syndrome, a rare genetic disorder characterized by relentless hunger. The acquisition aims to expand Neurocrine's portfolio in rare diseases.

Neurocrine Biosciences has announced its intention to acquire Soleno Therapeutics in a $2.9 billion deal, primarily to obtain a drug for Prader-Willi syndrome.

The deadline for leadership in a securities fraud lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) is approaching on May 5, 2026.

Investors in Soleno Therapeutics, Inc. (SLNO) are facing a May 5, 2026, deadline to participate in a securities fraud class action lawsuit.

Highlights from Soleno Therapeutics' fourth-quarter earnings call were published, detailing the company's recent financial results.

Neurocrine Biosciences has announced its intention to acquire Soleno Therapeutics in a transaction valued at $2.9 billion.

Soleno Therapeutics (SLNO) experienced a significant surge in its stock price on Monday. The article details the reasons behind this rapid increase in the company's market valuation.

Neurocrine Biosciences has announced its acquisition of Soleno Therapeutics, a move that will give Neurocrine control over a drug designed to treat a relentless hunger disorder.

Neurocrine Biosciences is set to acquire Soleno Therapeutics, thereby gaining access to a promising drug designed to treat a relentless hunger disorder.

Neurocrine Biosciences has announced an all-cash buyout of Soleno Therapeutics for $2.9 billion, valuing shares at $53 each, specifically to acquire a treatment for a rare disease that causes relentless hunger.

Neurocrine Biosciences announced its intent to acquire Soleno Therapeutics, thereby obtaining a drug designed to treat Prader-Willi syndrome, a disorder characterized by relentless hunger.

Investor sentiment for Soleno Therapeutics (SLNO) remains subdued, reflecting ongoing concerns about the company's growth prospects.

Investors in Soleno Therapeutics, Inc. (SLNO) are being offered an opportunity to lead a securities fraud class action lawsuit against the company.

Kaplan Fox has alerted investors to a securities class action lawsuit against Soleno Therapeutics, Inc. (SLNO), with a deadline for participation set for May 5, 2026.

Wells Fargo has reduced its price target for Soleno Therapeutics (SLNO) from $114 to $110, citing specific reasons for the adjustment.

Soleno Therapeutics reported GAAP EPS of $0.80, beating estimates by $0.09, and revenue of $91.73 million, surpassing estimates by $3.18 million.